Trusted by:
How a person’s immune system responds to a protein called LL-37 may increase risk for developing acute coronary syndrome, but the response may also serve as a potential target for future treatments.
In a new multicenter international study led by the Mayo Clinic Comprehensive Cancer Center, researchers found that people with the B-cell precursor subtype of acute lymphoblastic leukemia (BCP-ALL), who also lacked a genetic abnormality known as the Philadelphia chromosome and were in remission with no trace of cancer, showed significantly higher survival rates when blinatumomab was added to their chemotherapy treatment.
A new study has discovered genetic markers in inflammation that may be related to a second stroke or other major cardiovascular event following a stroke. These findings could help identify drug targets to mitigate stroke-related disability and mortality.
Relapsed B-cell ALL is the leading cause of cancer-related deaths in children and young adults. UniSA research has shown the potential of new microfluidic technology, to improve the CAR T-cell manufacturing process by efficiently removing contaminating cancerous cells and other large white blood cells - potentially leading to greater access and lower costs of treatment.
In 2022, Alaggio and colleagues revised the WHO Classification of Haematolymphoid Tumors resulting in elimination of the provisional diagnostic categories of Hairy Cell Leukemia Variant (HCLv) and B Prolymphocytic Leukemia.
A new study in mice hints at the promise of an eventual alternative treatment option for the “wet” version of age-related macular degeneration (AMD).
Vanderbilt University Medical Center (VUMC) researchers are touting data from a multicenter, international phase 2 clinical trial showing a new, curative treatment for sickle cell disease (SCD).
Indiana University School of Medicine researchers and their collaborators have uncovered molecular insights expected to enhance treatment options for acute myeloid leukemia (AML), a rare and severe blood and bone marrow cancer.
Heart attacks have been the leading cause of death in the U.S. for a century. While most treatments for cardiac events target breaking down blood clots, Georgia Tech researchers have found a way to prevent blood clots from even forming. Dramatically, their drug is shown to completely knock out the formation of blood clots without increasing the risks of bleeds in vivo.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right